ST-246 liquid formulations and methods
Inventors
Tyavanagimatt, Shanthakumar R. • Anderson, Melialani A. C. L. S. • Weimers, William • Kasi, Gopi Krishna • Samuel, N K Peter • Bolken, Tove C. • Hruby, Dennis E.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
Core Innovation
The invention concerns solubilizing poorly soluble ST-246 in a liquid formulation containing cyclodextrin and pharmaceutically acceptable ingredients. Hydroxypropyl-β-cyclodextrin (HP-β-CD) is identified as a preferred cyclodextrin, and the formulation accommodates ST-246 Forms I–VI. The formulation contains a therapeutically effective amount of ST-246 in a pharmaceutically acceptable liquid carrier.
The problem addressed is the poor solubility of ST-246. The disclosed solubility studies report that ST-246 solubility increases with increasing HP-β-CD concentration and temperature. The independent claim is described as a process for making the liquid formulation, with optional filtration identified and [procedural detail omitted for safety].
Figures 4 to 10 depict cyclodextrin structures and formulation data showing concentration- and condition-dependent ST-246 solubility, including effects of cyclodextrin type and level, temperature, pH, and dilution. The plotted results support cyclodextrin-based liquid formulations. Other figures show monkey pharmacokinetic profiles for intravenous and oral ST-246 dosing and diffraction patterns of ST-246 samples.
Claims Coverage
The provided claims identify one independent claim, claim 1, covering one inventive feature. The claim is described both as a process for making a liquid formulation and as a liquid formulation of the same components.
Liquid formulation containing ST-246 and cyclodextrin
The independent claim covers a liquid formulation, or a process for making it, comprising a therapeutically effective amount of ST-246, cyclodextrin, and one or more pharmaceutically acceptable ingredients in a pharmaceutically acceptable liquid carrier. Optional filtration is also identified in the claim. [procedural detail omitted for safety].
The independent claim focuses on a liquid formulation containing ST-246 and cyclodextrin in a pharmaceutically acceptable liquid carrier, and on a process for making it.
Stated Advantages
The disclosed formulation addresses the poor solubility of ST-246; the solubility studies report increasing ST-246 solubility with increasing HP-β-CD concentration and temperature.
Documented Applications
A liquid formulation comprising a therapeutically effective amount of ST-246, cyclodextrin, and pharmaceutically acceptable ingredients.
Interested in licensing this patent?